Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Names John B. Harlow Jr. President and Chief Operating Officer

Neutral Impact 4 of 5 leadership Written later

Larimar Therapeutics appointed John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026, under an employment agreement with a $560,000 base salary and a 40% target annual bonus. He previously served as Chief Commercial Officer at Esperion Therapeutics from November 2025 to September 2026, and the filing describes a new senior operating role for the company.

Key points

  • Appointment effective September 29, 2026, as President and Chief Operating Officer
  • Base salary of $560,000 per year, a $35,000 cash signing bonus, and a target annual bonus of 40% of base salary
  • Inducement grants include an option on 800,000 shares and restricted stock units covering 50,000 shares, vesting over multiple years
  • Severance of nine months of base salary and COBRA coverage, or twelve months of salary plus target bonus and COBRA if terminated within one year after a change in control

The filing

CompanyLarimar Therapeutics, Inc. (LRMR)
Form8-K, current report
Filed with the SECSep 29, 2026, 4:06 PM ET
Accession number0001193125-26-407331

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.